Core Viewpoint - The successful heart transplant following the use of the SynCardia Total Artificial Heart at UCSF Health marks a significant advancement in treating advanced biventricular heart failure, showcasing the clinical adoption of this technology in leading transplant centers [1][4]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the only provider of commercially available total artificial heart technology for patients with end-stage heart failure [6][7]. - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, and it remains the only commercially available artificial heart in the U.S. and Canada [6][7]. Clinical Milestone - UCSF Health successfully performed its first heart transplant on a patient who had been supported by the SynCardia Total Artificial Heart, marking it as the fifth case at UCSF [1][2][4]. - The patient, a 37-year-old from California's Central Valley, was implanted with the STAH in August 2025 and underwent a successful heart transplant three months later [2][3]. Surgical Details - The heart transplant procedures were conducted by Dr. Amy Fiedler and Dr. Jason W. Smith at the Helen Diller Medical Center, which is part of UCSF Health, known for having one of the largest heart transplant programs in the country [3][4]. Future Developments - Picard Medical is advancing the development of the Emperor TAH, a next-generation fully implantable device aimed at expanding access to long-term mechanical circulatory support without the need for external pneumatic drivers [4].